Table Graph
      published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKrolewiecki, 2020 0.49 [0.01; 26.05] 0.49[0.01; 26.05]Krolewiecki, 202010%45NAnot evaluable deathsdetailed resultsKrolewiecki, 2020 0.49 [0.01; 26.05] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] 0.24[0.02; 2.65]Krolewiecki, 2020, NCT04523831 (Mahmud), 202020%408moderatenot evaluable clinical deteriorationdetailed resultsNCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] 0.44[0.23; 0.84]NCT04523831 (Mahmud), 202010%363NAnot evaluable clinical improvementdetailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable clinical improvement (7-day)detailed resultsNCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] 1.93[1.27; 2.93]NCT04523831 (Mahmud), 202010%363NAnot evaluable clinical improvement (time to event analysis only)detailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable serious adverse eventsdetailed resultsKrolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] 2.14[0.21; 21.56]Krolewiecki, 2020, NCT04523831 (Mahmud), 202020%408moderatenot evaluable adverse eventsdetailed resultsKrolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] 3.80[0.36; 40.08]Krolewiecki, 2020, NCT04523831 (Mahmud), 2020259%408moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-07 02:51 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 684,886 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons